Intelligent Bio Solutions Inc. (NASDAQ:INBS) Sees Large Decrease in Short Interest

Intelligent Bio Solutions Inc. (NASDAQ:INBS) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 427,400 shares, a decrease of 5.1% from the December 31st total of 450,500 shares. Approximately 9.1% of the shares of the stock are short sold. Based on an average trading volume of 118,600 shares, the short-interest ratio is presently 3.6 days.

Intelligent Bio Solutions Stock Performance

NASDAQ INBS opened at $1.76 on Friday. The stock’s 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.50. Intelligent Bio Solutions has a one year low of $1.00 and a one year high of $11.70.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.17). Intelligent Bio Solutions had a negative net margin of 288.35% and a negative return on equity of 147.50%. The business had revenue of $872.29 million during the quarter. As a group, equities research analysts forecast that Intelligent Bio Solutions will post -1.25 EPS for the current fiscal year.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.